FranceFrance

Nicox glaucoma drug meets endpoints in Phase IIb study

14.03.2012

Sophia Antipolis/ Madison – French NicOx S.A. and the global eye health specialist Bausch & Lomb have announced positive top-line results from their phase 2b dose finding study with BOL-303259-X, a nitric oxide-donating version of Pfizer’s prostaglandin F2-alpha analogue latanoprost, in 400 patients with open-angle glaucoma or ocular hypertension. As shown in two previous Phase II trials conducted during NiCox’s partnership with Pfizer, which ran from 2004-2009, BOL-303259-X (previously NCX 116, PF-3187207) was superior to Pfizer’s lipophilic prostaglandin F2-alpha formulation latanoprost (Xalatan®). In 2 of 4 dose regimes, the NO-donating drug lowered intraocular pressure (IOP) better than Xalatan. On top of that, the responder rate was 68.7% for the most efficacious dose of BOL-303259-X, compared to 47.5% for Xalatan®. The most frequent side effect was reddening of the eyes (hyperemia). The results triggered a US-$10m milestone from Bausch & Lomb to its French partner. The US eye specialist announced it will initiate a global phase 3 development program for the eye drops. The firms believe that NO improves the IOP lowering effect of prostaglandin F2-alpha. In two Phase II trials completed in 2008, the drug was reported to be at least 20% more effective than Xalatan®, according to Pfizer, which re-licensed all development and commercialisation rights to NiCox in August 2009 after having refocused its drug development priorities.

FranceFrance

19.08.2011

Marcy l’Etoile – French in vitro diagnostics group Biomérieux S.A. informed the markets that it has acquired Argene, a French company specialising in molecular diagnostics for immuno­compromised patients. Biomérieux said it was...

FranceFrance

17.08.2011

Paris – A team consisting of French scientists and biotech start-up Epixis SA has developed a novel hepatitis C vaccine based on retrovirus-derived virus-like particles (VLPs) pseudotyped with the heterologous viral envelope...

FranceFrance

10.08.2011

Neuilly/New York - Les Laboratoires Servier and Intercept Pharmaceuticals join forces for the development of diabetes drugs. France’s largest independent pharmaceutical company and the US biotech entered into a worldwide ex-U.S....

FranceFrance

20.07.2011

Paris/New Haven - Sanofi pays a $9m milestone payment to Rib-X Pharmaceuticals, Inc. The French pharmaceutical company recently signed worldwide research collaboration and option for license for novel classes of antibiotics...

FranceFrance

12.07.2011

French drug maker Sanofi SA announced mixed results of a late-stage trial of multiple sclerosis drug Lemtrada. The two-year study CARE-MS I is the first of two randomised, Phase 3 clinical trials comparing Sanofi's alemtuzumab to...

FranceFrance

05.07.2011

French Biotech BioAlliance Pharma S.A. has announced plans to raise up toEUR 16.6 million through the sale 3.4 million shares at EUR 4.90 in a rightsissue. The price is a 20% discount to BioAlliance's closing price of EUR6.10...

FranceFrance

14.06.2011

Paris – Pulmonary arterial hypertension (PAH), a severe disease of the arterial blood vessels in the lungs, leads to chronically elevated pulmonary artery pressure and remodelling of the small pulmonary arteries (SMPs) as a...

FranceFrance

11.06.2011

Montpellier – French researchers have identified the factor that renders human dendritic and myeloid cells largely refractory to HIV-1 infection. Overexpression of the SAMHD1 protein in cell culture effectively blocked infection...

Displaying results 21 to 30 out of 268

< Previous 21-30 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-france/browse/2/article/nicox-glaucoma-drug-meets-endpoints-in-phase-iib-study.html

Print Magazine

Event Video

All videos

Events

All Events

Stock list

All quotes

TOP

  • VITA 344.32 EUR6.67%
  • MORPHOSYS74.44 EUR4.04%
  • STRATEC BIOMEDICAL39.84 EUR3.94%

FLOP

  • CYTOS0.16 CHF-5.88%
  • CO.DON2.75 EUR-3.17%
  • ADDEX3.30 CHF-2.94%

TOP

  • BIOFRONTERA2.90 EUR31.2%
  • VITA 344.32 EUR8.0%
  • BB BIOTECH157.70 EUR7.3%

FLOP

  • PAION2.24 EUR-30.0%
  • CYTOS0.16 CHF-27.3%
  • MAGFORCE5.90 EUR-17.5%

TOP

  • SANTHERA85.50 CHF2335.9%
  • CO.DON2.75 EUR192.6%
  • PAION2.24 EUR163.5%

FLOP

  • CYTOS0.16 CHF-95.8%
  • THERAMETRICS0.08 CHF-42.9%
  • 4SC0.97 EUR-42.6%

No liability assumed, Date: 23.10.2014


Current issue

All issues

Product of the week

Products